South Africa registers a new immunotherapy for recurrent or metastatic nasopharyngeal carcinoma, according to IOL (South Africa). The treatment targets a rare cancer described as aggressive, and is intended for people whose disease has returned after prior treatment or has spread to other parts of the body. The reporting frames the registration as a breakthrough, indicating the therapy has received regulatory approval for this specific patient group in the country. Based on the available information, details such as the drug’s name, the type of immunotherapy, trial results, eligibility criteria, and timelines for access or availability are not provided in the source summary. The announcement focuses on the fact of registration in South Africa and the indicated use—recurrent or metastatic nasopharyngeal carcinoma—rather than on broader context or comparisons with existing options. No additional outlets or corroborating details were included in the material provided here, so the summary reflects only what is stated in the given source.